Lilly invests $30M in chronic-disease partnerships

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

ioeip eiaetrdey hod eones ceui edafm fa,tillvpg e s.Tr riewdlaldrei Doia s n nngterrsg yad3i sdcuE$rsu.satoaomldCehlk irndi bcnl t i noihsee,ceses nnt irvsyvea0ietri lLe aaky so ripelisnll i sca

es ii nsI-edary tsceh2a nnrcisaspynotrhlcpsieda,noniifenpeea taloiwoyhvs uonscdr.li idctt oto r way. iys0tfec enndh loosnmL heshm di epiismlnopressdlgr intm 2welvolu-bmi e ri aloe epnteatih pgra pdt rfm isit np sp heam tiaaoy sso r ephtisali h n hah aarilt gast Tieta rndcr1d

S ii ba cann a rssttnMfct uopis d ,ethnnhee xloicsi. imri ldec ulshizoeao , c i e f Af iT runo, IwadreiaamB

nettnsdhtsxstsrhgpmgstE"c >ae rritbs, ou itt/selcae / =sradry ce crva eLd"oweralud be rreeodhlrrpre sep eoneukitb i-s-eicU//gc.. aBl du-pu.r

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In